,.
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):60. doi: 10.1167/iovs.61.6.60.
To determine whether lysophospholipid (LPL) profiles and corresponding conversion enzymes in the LPL pathways are altered in the optic nerve (ON) between human control and glaucoma samples.
Lipids extracted from control (n = 11) and glaucomatous (n = 12) ON samples using the Bligh and Dyer method were subjected to high-resolution mass spectrometry on a Q-exactive mass spectrometer coupled with a high-performance liquid chromatography (Accela 600) system. Analysis was performed for LPLs (lysophosphatidylcholines, lysophosphatidylserines, lysophosphatidylethanolamines, lysophosphatidylinositols, and lysosphingomyelines) using LipidSearch v.4.1, MZmine v.2.0, and MetaboAnalyst v.4.0. LPL synthesis and degradation pathway maps, utilizing UniProt and BRENDA database entries as needed, were created using Kyoto Encyclopedia of Genes and Genomes (KEGG)-based tools. The mRNA expression level in normal and glaucomatous human ON were analyzed using Gene Expression Omnibus (GEO) entry GSE45570. Protein amounts were determined using PHAST gel and dot blot and were used for normalization of protein amounts across samples. Western blot, ELISA, and protein quantification were performed using established protocols.
Principal component analysis of ON LPL profile placed control and glaucomatous ONs in two distinct separate groups. Mass spectrometric analysis of ON revealed decrease in lysophosphatidic acid, lysophosphatidylethanolamine, lysophosphatidylcholine, and significant increase in diacylglycerol in glaucomatous ON. Statistical analysis of LPL conversion enzymes revealed significant overexpression of phosphatidate phosphatase LPIN2, phospholipid phosphatase 3, phosphatidylcholine-sterol acyltransferase, and calcium-dependent phospholipase 2, and significant downregulation of glycerol-3-phosphate acyltransferase 4 at mRNA level in glaucomatous ON. Western blot and ELISA confirmed proteomic differences between normal and diseased ON.
Our analysis revealed alterations in specific LPL levels and corresponding select enzyme-level changes in glaucomatous ON.
确定人眼视神经(ON)中溶血磷脂(LPL)谱及其相应的 LPL 通路转换酶在对照和青光眼样本之间是否发生改变。
使用 Bligh 和 Dyer 法从对照(n = 11)和青光眼(n = 12)ON 样本中提取脂质,然后在配备高效液相色谱(Accela 600)系统的 Q-Exactive 质谱仪上进行高分辨质谱分析。使用 LipidSearch v.4.1、MZmine v.2.0 和 MetaboAnalyst v.4.0 对 LPL(溶血磷脂酰胆碱、溶血磷脂酰丝氨酸、溶血磷脂酰乙醇胺、溶血磷脂酰肌醇和溶血神经鞘磷脂)进行分析。利用 UniProt 和 BRENDA 数据库条目,创建 LPL 合成和降解途径图谱,利用京都基因与基因组百科全书(KEGG)工具。使用基因表达综合数据库(GEO)条目 GSE45570 分析正常和青光眼人 ON 中的 mRNA 表达水平。使用 PHAST 凝胶和点印迹法测定蛋白质含量,并用于跨样本的蛋白质定量标准化。使用既定方案进行 Western blot、ELISA 和蛋白质定量。
ON LPL 图谱的主成分分析将对照和青光眼 ON 置于两个截然不同的独立组中。对 ON 的质谱分析显示,青光眼 ON 中的溶血磷脂酸、溶血磷脂酰乙醇胺、溶血磷脂酰胆碱减少,二酰基甘油显著增加。对 LPL 转换酶的统计分析显示,青光眼 ON 中磷酸酶 LPIN2、磷酸脂酶 3、磷脂酰胆碱-固醇酰基转移酶和钙依赖性磷酸酶 2 的 mRNA 表达显著上调,甘油-3-磷酸酰基转移酶 4 显著下调。Western blot 和 ELISA 证实了正常和患病 ON 之间的蛋白质组差异。
我们的分析表明,在青光眼 ON 中存在特定 LPL 水平的改变以及相应的选择性酶水平变化。